Biology of Blood and Marrow Transplantation
Volume 13, Issue 12 , Pages 1515-1524 , December 2007

CD3+ Cell Dose and Disease Status Are Important Factors Determining Clinical Outcomes in Patients Undergoing Unmanipulated Haploidentical Blood and Marrow Transplantation after Conditioning Including Antithymocyte Globulin

  • Lujia Dong

      Affiliations

    • Peking University, People's Hospital
    • Dao-Pei Hospital, Beijing, China
    • Corresponding Author InformationCorrespondence and reprint requests: Lujia Dong, MD, Peking University, People's Hospital, No.11 Xizhimen South Street, Beijing 100044, China. Tel: 8610 68792784; Fax: 8610 68333439.
    • ,
  • Tong Wu

      Affiliations

    • Peking University, People's Hospital
    • Dao-Pei Hospital, Beijing, China
    • ,
  • Mei-Jie Zhang

      Affiliations

    • Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, USA
    • ,
  • Zhi-Yong Gao

      Affiliations

    • Peking University, People's Hospital
    • Dao-Pei Hospital, Beijing, China
    • ,
  • Dao-Pei Lu

      Affiliations

    • Peking University, People's Hospital
    • Dao-Pei Hospital, Beijing, China

Received 6 June 2007 ,Accepted 9 September 2007.

  • Image Result

    Cumulative incidence of outcomes of haploidentical HCT for patients with leukemia. A, ANC (P = 1.0000 at day 100). B, Platelet engraftment (P = .3626 at day 100). C, aGVHD, grade 2-4 (P = .1165 at day

    Cumulative incidence of outcomes of haploidentical HCT for patients with leukemia. A, ANC (P = 1.0000 at day 100). B, Platelet engraftment (P = .3626 at day 100). C, aGVHD, grade 2-4 (P = .1165 at day 100). D, aGVHD, grade 3-4 (P = .5449 at day 100). E, Relapse (P = .3962 at 2 years). F, TRM (P = .0181 at 2 years).

  • Image Result
    Adjusted probabilities of LFS and OS after haploidentical HCT for patients with leukemia (adjusted for early, intermediate, and advanced disease status). A, Adjusted probability of LFS (P = .0115 at 2

    Adjusted probabilities of LFS and OS after haploidentical HCT for patients with leukemia (adjusted for early, intermediate, and advanced disease status). A, Adjusted probability of LFS (P = .0115 at 2 years). B, Adjusted probability of OS (P = .0075 at 2 years).

PII: S1083-8791(07)00455-7

doi: 10.1016/j.bbmt.2007.09.007

Biology of Blood and Marrow Transplantation
Volume 13, Issue 12 , Pages 1515-1524 , December 2007

Article Tools

* Image Usage & Resolution